
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Σκοπός του Ιntelligence-pharma είναι να σας ενημερώνει για τις τελευταίες τάσεις και αναλύσεις σχετικά με τον ταχέως μεταβαλλόμενο κόσμο του φαρμάκου.
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Merck’s Keytruda Fails in Late-Stage HCC Trial
Marketing
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Keytruda Combination Set to Become a Cornerstone Therapy in Renal Cell Carcinoma
Novartis’ Busy Day: 10-Target Deal With AbCellera and FDA Approves Parasite Drug
Merck Eyes Plans Phase III Programs in Prostate Cancer With Keytruda
Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
ASCO GU Preview: Merck, Bristol-Myers Squibb, Pfizer and More
Glaxo adds flesh to its oncology ambitions
Upcoming events – Cancer readouts for Merck & Co and Seattle
GSK-MERCK: Συνεργάζονται για μια νέα ανοσοθεραπεία κατά του καρκίνου
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
FDA Action Alert: Sanofi, Motif Bio and Merck
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s … Continue Reading Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns Over Drug Pricing
0 Takeover Targets to Watch in 2019
The 2019 pipeline report: Changing the treatment paradigm